|
1
|
Arai E and Kanai Y: Genetic and epigenetic
alterations during renal carcinogenesis. Int J Clin Exp Pathol.
4:58–73. 2010.PubMed/NCBI
|
|
2
|
Gupta K, Miller JD, Li JZ, Russell MW and
Charbonneau C: Epidemiologic and socioeconomic burden of metastatic
renal cell carcinoma (mRCC): A literature rereview. Cancer Treat
Rev. 34:193–205. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Deng FM and Melamed J: Histologic variants
of renal cell carcinoma: Does tumor type influence outcome? Urol
Clin North Am. 39:119–132. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Hartmann JT and Bokemeyer C: Chemotherapy
for renal cell carcinoma. Anticancer Res. 19(2C): 1541–1543.
1999.PubMed/NCBI
|
|
5
|
Yu DS, Chang SY and Ma CP: The expression
of mdr-1-related gp-170 and its correlation with anthracycline
resistance in renal cell carcinoma cell lines and
multidrug-resistant sublines. Br J Urol. 82:544–547. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Lin JA, Fang SU, Su CL, Hsiao CJ, Chang
CC, Lin YF and Cheng CW: Silencing glucose-regulated protein 78
induced renal cell carcinoma cell line G1 cell-cycle arrest and
resistance to conventional chemotherapy. Urol Oncol.
32:29.e1–29.e11. 2014. View Article : Google Scholar
|
|
7
|
Vos JW, Pieuchot L, Evrard JL, Janski N,
Bergdoll M, de Ronde D, Perez LH, Sardon T, Vernos I and Schmit AC:
The plant TPX2 protein regulates prospindle assembly before nuclear
envelope breakdown. Plant Cell. 20:2783–2797. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Trieselmann N, Armstrong S, Rauw J and
Wilde A: Ran modulates spindle assembly by regulating a subset of
TPX2 and Kid activities including Aurora-A activation. J Cell Sci.
116:4791–4798. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Gruss OJ, Wittmann M, Yokoyama H,
Pepperkok R, Kufer T, Silljé H, Karsenti E, Mattaj IW and Vernos I:
Chromosome induced microtubule assembly mediated by TPX2 is
required for spindle formation in HeLa cells. Nat Cell Biol.
4:871–879. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
10
|
Anderson MR, Harrison R, Atherfold PA,
Campbell MJ, Darnton SJ, Obszynska J and Jankowski JA: Met receptor
signaling: A key effector in esophageal adenocarcinoma. Clin Cancer
Res. 12:5936–5943. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Kan T, Sato F, Ito T, Matsumura N, David
S, Cheng Y, Agarwal R, Paun BC, Jin Z, Olaru AV, et al: The
miR-106b-25 polycistron, activated by genomic amplification,
functions as an oncogene by suppressing p21 and Bim.
Gastroenterology. 136:1689–1700. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Tonon G, Wong KK, Maulik G, Brennan C,
Feng B, Zhang Y, Khatry DB, Protopopov A, You MJ, Aguirre AJ, et
al: High-resolution genomic profiles of human lung cancer. Proc
Natl Acad Sci USA. 102:9625–9630. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Gruss OJ, Wittmann M, Yokoyama H,
Pepperkok R, Kufer T, Silljé H, Karsenti E, Mattaj IW and Vernos I:
Chromosome-induced microtubule assembly mediated by TPX2 is
required for spindle formation in HeLa cells. Nat Cell Biol.
4:871–879. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
14
|
Kufer TA, Silljé HH, Körner R, Gruss OJ,
Meraldi P and Nigg EA: Human TPX2 is required for targeting
Aurora-A kinase to the spindle. J Cell Biol. 158:617–623. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Lin DM, Ma Y, Xiao T, Guo SP, Han NJ, Su
K, Yi SZ, Fang J, Cheng SJ and Gao YN: TPX2 expression and its
significance in squamous cell carcinoma of lung. Zhonghua Bing Li
Xue Za Zhi. 35:540–544. 2006.(In Chinese). PubMed/NCBI
|
|
16
|
Shigeishi H, Ohta K, Hiraoka M, Fujimoto
S, Minami M, Higashikawa K and Kamata N: Expression of TPX2 in
salivary gland carcinomas. Oncol Rep. 21:341–344. 2009.PubMed/NCBI
|
|
17
|
Liu HC, Li YY, Liu YH and Liu HY:
Expression of TPX2 mRNA and its correlation with clinical pathology
in esophageal cancer. J Clin Exp Pathol. 26:151–153. 2010.
|
|
18
|
Colak D, Nofal A, Albakheet A, Nirmal M,
Jeprel H, Eldali A, Al-Tweigeri T, Tulbah A, Ajarim D, Malik OA, et
al: Age-specific gene expression signatures for breast tumors and
cross-species conserved potential cancer progression markers in
young women. PLoS One. 8:e632042013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Yan L, Li S, Xu C, Zhao X, Hao B, Li H and
Qiao B: Target protein for Xklp2 (TPX2), a microtubule-related
protein, contributes to malignant phenotype in bladder carcinoma.
Tumour Biol. 34:4089–4100. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Wei P, Zhang N, Xu Y, Li X, Shi D, Wang Y,
Li D and Cai S: TPX2 is a novel prognostic marker for the growth
and metastasis of colon cancer. J Transl Med. 11:3132013.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
El-Serag HB, Davila JA, Petersen NJ and
McGlynn KA: The continuing increase in the incidence of
hepatocellular carcinoma in the United States: An update. Ann
Intern Med. 139:817–823. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Cáceres-Gorriti KY, Carmona E, Barrès V,
Rahimi K, Létourneau IJ, Tonin PN, Provencher D and Mes-Masson AM:
RAN nucleo-cytoplasmic transport and mitotic spindle assembly
partners XPO7 and TPX2 are new prognostic biomarkers in serous
epithelial ovarian cancer. PLoS One. 9:e910002014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Liu HC, Zhang Y, Wang XL, Qin WS, Liu YH,
Zhang L and Zhu CL: Upregulation of the TPX2 gene is associated
with enhanced tumor malignance of esophageal squamous cell
carcinoma. Biomed Pharmacother. 67:751–755. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Liu HC, Liu YH, Li SL, Gao DL, Zhang L,
Pang X, Zheng XY and Zhang YH: Expression of TPX2 and Aurora A in
esophageal squamous carcinoma and their significance in clinical
pathology. Cancer Res Prev Treat. 36:932–935. 2009.
|
|
25
|
Elmore JM, Kadesky KT, Koeneman KS and
Sagalowsky AI: Reassessment of the 1997 TNM classification system
for renal cell carcinoma. Cancer. 98:2329–2234. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Hong SK, Jeong CW, Park JH, Kim HS, Kwak
C, Choe G, Kim HH and Lee SE: Application of simplified Fuhrman
grading system in clear-cell renal cell carcinoma. BJU Int.
107:409–415. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Shigeishi H, Fujimoto S, Hiraoka M, Ono S,
Taki M, Ohta K, Higashikawa K and Kamata N: Overexpression of the
receptor for hyaluronan-mediated motility, correlates with
expression of microtubule-associated protein in human oral squamous
cell carcinomas. Int J Oncol. 34:1565–1571. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Pascreau G, Eckerdt F, Lewellyn AL,
Prigent C and Maller JL: Phosphorylation of p53 is regulated by
TPX2-Aurora A in xenopus oocytes. J Biol Chem. 284:5497–5505. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Stewart S and Fang G: Anaphase-promoting
complex/cyclosome controls the stability of TPX2 during mitotic
exit. Mol Cell Biol. 25:10516–10527. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Ozlü N, Srayko M, Kinoshita K, Habermann
B, O'toole ET, Müller-Reichert T, Schmalz N, Desai A and Hyman AA:
An essential function of the C. elegans ortholog of TPX2 is to
localize activated aurora A kinase to mitotic spindles. Dev Cell.
9:237–248. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Scharer CD, Laycock N, Osunkoya AO, Logani
S, McDonald JF, Benigno BB and Moreno CS: Aurora kinase inhibitors
synergize with paclitaxel to induce apoptosis in ovarian cancer
cells. J Transl Med. 6:792008. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Gao J, Ding F, Liu Q and Yao Y: Knockdown
of MACC1 expression suppressed hepatocellular carcinoma cell
migration and invasion and inhibited expression of MMP2 and MMP9.
Mol Cell Biochem. 376:21–32. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Crane R, Gadea B, Littlepage L, Wu H,
Ruderman JV and Aurora A: meiosis and mitosis. Biol Cell.
96:215–229. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Leng J, Han C, Demetris AJ, Michalopoulos
GK and Wu T: Cyclooxygenase-2 promotes hepatocellular carcinoma
cell growth through Akt activation: Evidence for Akt inhibition in
celecoxib induced apoptosis. Hepatology. 38:756–768. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Wang YH, Dong YY, Wang WM, Xie XY, Wang
ZM, Chen RX, Chen J, Gao DM, Cui JF and Ren ZG: Vascular
endothelial cells facilitated HCC invasion and metastasis through
the Akt and NF-κB pathways induced by paracrine cytokines. J Exp
Clin Cancer Res. 32:512013. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Matsubara N, Mukai H, Naito Y, Itoh K,
Komai Y and Sakai Y: First experience of active surveillance before
systemic target therapy in patients with metastaticrenal cell
carcinoma. Urology. 82:118–123. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Waalkes S, Kramer M, Herrmann TR, Schrader
AJ, Kuczyk MA and Merseburger AS: Present state of target therapy
for disseminated renal cell carcinoma. Immunotherapy. 2:393–398.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Engelman JA, Luo J and Cantley LC: The
evolution of phosphatidylinositol 3-kinases as regulators of growth
and metabolism. Nat Rev Genet. 7:606–619. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Robb VA, Karbowniczek M, Klein-Szanto AJ
and Henske EP: Activation of the mTOR signaling pathway in renal
clear cell carcinoma. J Urol. 177:346–352. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Manning BD and Cantley LC: United at last:
The tuberous sclerosis complex gene products connect the
phosphoinositide 3-kinase/Akt pathway to mammalian target of
rapamycin (mTOR) signalling. Biochem Soc Trans. 31:573–578. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Dasanu CA, Clark BA III and Alexandrescu
DT: mTOR-blocking agents in advanced renal cancer: An emerging
therapeutic option. Expert Opin Investig Drugs. 18:175–187. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Hudes GR: mTOR as a target for therapy of
renal cancer. Clin Adv Hematol Oncol. 5:772–774. 2007.PubMed/NCBI
|
